GLPwatch
Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
Diabetes Res Clin Pract · 2013
Last updated 2026-05-28In a study of 30 people with newly diagnosed type 1 diabetes, adding either exenatide or sitagliptin to insulin therapy reduced the amount of insulin needed. However, these drugs did not increase the body's own insulin production or raise the risk of low blood sugar events.
AI summary of the abstract below.
| Journal | Diabetes Res Clin Pract, 2013 |
|---|---|
| Citations | 82 |
| Relative citation ratio | 2.72 |
| NIH percentile | 82 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
Incretin based therapies are known to have pleotropic benefits in type 2 diabetes but have not been studied in new onset type 1 diabetes. In this randomized, open label study, we investigated the effect of the addition of exenatide or sitagliptin to insulin in patients with new onset type 1 diabetes. Our data suggest that the addition of exenatide and sitagliptin decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events.
Verbatim abstract via PubMed 23490599 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.